Related Studies Sample Clauses

Related Studies. The agreement by the Parties to any Additional Study under this Section 4.4, whether from the outset of the study pursuant to Sections 4.4(a) or 4.4(b), or through either Party's exercise of its Opt-In Right to an Incremental Study pursuant to Section 4.4(c)(v), shall be deemed an agreement by the Parties to cooperate in any and all related studies necessary for the implementation of such Additional Study or to obtain Drug Approval in the U.S. and all Major Market Countries in the applicable new Indication or new formulation that is the subject of such Additional Study (excluding any related studies that are required exclusively to obtain Drug Approval in the U.S. and not in any Major Market Country) (each such related 33 [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. study, a "Related Study"). The terms of Section 4.4 shall apply to any Related Study in the same manner that they apply to the Additional Study to which such Related Study relates.
View SourceView Similar (2)
Related Studies. In 1981, Lamport [9] first proposed a remote password authentication protocol for insecure channels, and since then, many authentication protocols have been studied [10–24], in order to enhance security and efficiency. In 2006, ▇▇▇▇ et al. [10] proposed a password-based user authentication scheme with a light computational overhead using a one-way hash function and exclusive-OR operations. However, ▇▇▇▇▇ et al. [11] pointed out that ▇▇▇▇ et al.’s scheme [10] could not resist replay and forgery attacks, and then proposed an enhanced scheme. They claimed that their scheme was secure against reply and forgery attacks, and that it provided improved efficiency in the password change process. In 2009, ▇▇▇▇▇▇ et al. [12] described how neither the schemes provided by ▇▇▇▇ et al. [10] and ▇▇▇▇▇ et al. [11] were secure against replay attacks and man-in-the-middle attacks. They also proposed a robust user authentication scheme for the WSN environment. In the same year, Das [13] proposed an enhanced authentication scheme as the basis for ▇▇▇▇ et al.’s scheme [10]. He insisted that their scheme can resist different types of attacks, such as many logged-in-users with the same login identity attacks, off-line password guessing attacks, stolen-verifier attacks and impersonation attacks. However, ▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇ [14] pointed out in 2010 that ▇▇▇’s scheme [13] could not resist gateway node bypassing attacks and privileged-insider attacks, and thus proposed an improved authentication scheme. In the same year, ▇▇▇▇▇▇ et al. [15] demonstrated that ▇▇▇’s scheme [13] and Khan-Alghathbar’s scheme [14] could not resist stolen smart card attacks, and they then proposed a enhanced version. ▇▇▇▇ and ▇▇▇▇ [16] also pointed out that Das scheme [13] could not resist parallel session attacks, and did not provide mutual authentication. In 2011, ▇▇▇ et al. [17] proposed a user authentication protocol for two-tiered wireless sensor networks, and Yeh et al. [18] proposed an authentication protocol based on elliptic curves cryptography. In 2012, ▇▇▇ et al. [19] and ▇▇▇ et al. [20] proposed a user authentication and key agreement scheme for WSNs based on the use of a smart card. These were both designed to fulfill various security requirements, such as key agreement, mutual authentication, password protection and prevention against several attacks. In 2014, ▇▇▇▇ [21] proposed an user authentication scheme based on biometric technique for WSNs. In the same year, Turkanovic´ et al. [22] prop...
View Source
Related Studies. A number of studies have been conducted that are related to the current study. One research group evaluated the strength of wellness policies of Georgia public schools but employed a different methodology than that of the current study.48 Instead of administering a survey, the authors assessed the strength of school wellness policies in relation to school demographics by reviewing actual copies of the schools’ wellness policies.48 It was found that having well-defined goals for the wellness policies as well as nutrition education was positively associated with student academic performance.48 It was also found that only 51% of school districts’ policies complied with all required components of the CNR, which may indicate that it would be beneficial to provide financial and/or technical assistance to schools.48 This study is particularly relevant to the current study because the population includes Georgia public schools and one exposure variable assessed was percentage of economically disadvantaged students.48 One author also studied the association of school nutrition wellness policies and environments in relation to certain school demographic characteristics in a national sample of public elementary, middle, and high schools.48 Similarly to the current study, food environments were compared to a number of similar school demographic characteristics.12,26 The authors assigned each school a composite score of its school food environment and policies (SFEP) based on an analysis of data from the 2005 School Nutrition and Dietary Assessment – III survey.12 There was no significant correlation between FRL rate and SFEPs or between percentage of students that were racial/ethnic minorities and SFEPs.48 This study measured many of the same demographic and school characteristics as the current study, but did not explicitly employ the SEM as a framework.12 On the other hand, one research team investigated school food environments in relation to school demographics in Pennsylvania high schools through administering a survey to foodservice directors and found that FRL rate was a significant predictor of a la carte sales.49 Finally, another research team examined school wellness policies and their barriers to implementation by surveying and conducting focus groups with a nationally representative sample of schools, but did not compare disparities in policy implementation across school demographics.36 The authors found that school board members had the highest confidence...
View Source
Related Studies. A case study conducted about Haagen-▇▇▇▇’s Blue Ocean Strategy (Del Mundo, 2008) determined customer satisfaction through a post-decision behavior quantification. A survey among 90 customers showed the presence of brand loyalty through repeat purchase intent and brand preference. ▇▇▇▇▇▇▇▇▇ (2007) conducted a descriptive study on the integrated marketing and public relations campaign of Toyota Motor Philippines. Through the analysis of interviews with three respondents, it was found out that Toyota has an inclination towards horizontal strategy in coordinating with workers. A study on Sun Cellular’s corporate image (Faelnar, 2007) revealed that the company uses advertising materials as their public relations tools and that there’s more positive perception towards the company. The study used key informant interviews and focus group discussions to gather the data. The frame alignment of Smart Communications and their target market on the company’s corporate identity was measured through a key informant interview and a survey with 105 respondents (▇▇▇▇▇▇▇, 2010). The study yielded that both parties view Smart Communications in the same way. These studies focused on the various companies’ campaign and how it affected the corporate image but no studies were made yet about disaster management and how it was perceived by the people.
View Source
Related Studies. Besides the research described so far, we performed a number of other aerosol-related studies, which resulted in papers that were published or are in press. The Gent PM10 sampler was further characterised [▇▇▇▇▇ et al., 1997]; work was done on the applicability of XRF with capillary optics for analysing aerosol samples [▇▇▇▇▇▇▇▇ et al., 1997], and on the use of the NMP for individual particle analysis [▇▇▇▇▇▇▇▇ et al., 1997d]. The elemental mass size distributions, as derived from cascade impactor measurements, were examined for a site near Rome [Maenhaut et al., 1999c] and the long-term data set from SFU samplings on the Antarctic Peninsula was analysed [▇▇▇▇▇▇▇ et al., 1998]. The aerosol composition and deposition were examined in eastern Germany [▇▇▇▇▇▇▇▇▇▇▇ et al., 2000]. Urban aerosols were studied in Cracow, Poland [▇▇▇▇▇▇ et al., 1999, 2000], in Helsinki, Finland [▇▇▇▇▇▇▇▇ et al., 1999, 2000, 2001a, 2001b, 2001c], and in Budapest, Hungary [Salma et al., 2000a, 2000b, 2000c, 2001a, 2001b, 2001c]. These urban studies were to some extent linked to the EUROTRAC-2 AEROSOL subproject. Furthermore, the work in Helsinki fitted within the EUROTRAC-2 project SATURN.
View Source
Related Studies. The agreement by the Parties to any Additional Study under this Section 4.4, whether from the outset of the study pursuant to Section 4.4(a) or (b), or through either Party’s exercise of its Opt-In Right to an Incremental Study pursuant to Section 4.4(c)(v), shall not be deemed an agreement by the Parties to cooperate in any and all related studies necessary for the implementation of such Additional Study or to obtain Drug Approval in the U.S. and all Major Market Countries in the applicable new Indication or new formulation that is the subject of such Additional Study (excluding any related studies that are required exclusively to obtain Drug Approval in the U.S. and not in any Major Market Country) (each such related study, a “Related Study”). Upon the agreement by the Parties to any Additional Study under this Section 4.4, the Parties shall use good faith efforts to discuss and agree on the terms (including design, budget, timeline and rights and obligations upon wind-down or termination) under which they will cooperate in any Related Studies that may be necessary. If, after discussion, the Parties cannot agree on the terms (including design, budget, timeline and rights and obligations upon wind-down or termination) under which they will cooperate in such Related Study, (i) the conducting Party may conduct the Related Study and shall be solely responsible for such conduct and the costs of such Related Study, and (ii) the terms of Section 4.4 shall apply to any such Related Study as if such Related Study is an Incremental Study. If the Parties agree on the terms of any Related Study, the terms of Section 4.4 shall apply to any Related Study in the same manner that they apply to the Additional Study to which such Related Study relates.
View Source

Related to Related Studies

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Regulatory Filings (a) Each of Parent and Acquisition Sub (and their respective Affiliates, if applicable), on the one hand, and the Company, on the other hand, shall (x) file with the FTC and the Antitrust Division of the DOJ a Notification and Report Form relating to this Agreement and the transactions contemplated hereby as required by the HSR Act as soon as reasonably practicable from the date following execution and delivery of this Agreement but in no event later than ten (10) Business Days following the execution and delivery of this Agreement, and (y) file comparable pre-merger or post-merger notification filings, forms and submissions with any foreign Governmental Authority that is required by any other Antitrust Laws as soon as reasonably practicable from the date following execution and delivery of this Agreement but in no event later than ten (10) Business Days following the execution and delivery of this Agreement. Each of Parent and the Company shall (i) cooperate and coordinate with the other in the making of such filings, (ii) supply the other with any information that may be required in order to make such filings, (iii) supply any additional information that reasonably may be required or requested by the FTC, the DOJ or the Governmental Authorities of any other jurisdiction in which any such filing is made under any other Antitrust Laws, and (iv) use reasonable best efforts to take all action necessary to cause the expiration or termination of the applicable waiting periods under the HSR Act or other Antitrust Laws as soon as practicable, and to obtain any required consents under any other Antitrust Laws applicable to the Offer and/or the Merger as soon as practicable, and to avoid any impediment to the consummation of the Offer or the Merger under any Antitrust Laws, including using reasonable best efforts to take all such action as reasonably may be necessary to resolve such objections, if any, as the FTC, the DOJ, or any other Governmental Authority or Person may assert under any applicable Antitrust Laws with respect to the Offer and/or the Merger. (b) Each of Parent and Acquisition Sub (and their respective Affiliates, if applicable), on the one hand, and the Company, on the other hand, shall promptly inform the other of any communication from any Governmental Authority regarding any of the transactions contemplated by this Agreement in connection with any filings or investigations with, by or before any Governmental Authority relating to this Agreement or the transactions contemplated hereby, including any proceedings initiated by a private party. If any party hereto or Affiliate thereof shall receive a request for additional information or documentary material from any Governmental Authority with respect to the transactions contemplated by this Agreement pursuant to the HSR or any other Antitrust Laws with respect to which any such filings have been made, then such party shall use its reasonable best efforts to make, or cause to be made, as soon as reasonably practicable and after consultation with the other party, an appropriate response in compliance with such request. In connection with and without limiting the foregoing, to the extent reasonably practicable and unless prohibited by applicable Law or by the applicable Governmental Authority, the parties hereto agree to (i) give each other reasonable advance notice of all meetings with any Governmental Authority relating to the Offer or the Merger, (ii) give each other an opportunity to participate in each of such meetings, (iii) keep the other party reasonably apprised with respect to any oral communications with any Governmental Authority regarding the Offer or the Merger, (iv) cooperate in the filing of any analyses, presentations, memoranda, briefs, arguments, opinions or other written communications explaining or defending the Offer and the Merger, articulating any regulatory or competitive argument and/or responding to requests or objections made by any Governmental Authority, (v) provide each other with a reasonable advance opportunity to review and comment upon, and consider in good faith the views of the other with respect to, all written communications (including any analyses, presentations, memoranda, briefs, arguments and opinions) with a Governmental Authority regarding the Offer and the Merger, (vi) provide each other (or counsel of each party, as appropriate) with copies of all written communications to or from any Governmental Authority relating to the Offer or the Merger, and (vii) cooperate and provide each other with a reasonable opportunity to participate in, and consider in good faith the views of the other with respect to, all material deliberations with respect to all efforts to satisfy the conditions set forth in clauses (A) and (C)(1) of Annex A and Section 9.1(c). Any such disclosures, rights to participate or provisions of information by one party to the other may be made on a counsel-only basis to the extent required under applicable Law or as appropriate to protect confidential business information or the attorney client privilege or attorney work product. (c) Each of Parent, Acquisition Sub and the Company shall cooperate with one another in good faith to (i) promptly determine whether any filings not contemplated by Section 8.2(a) are required to be or should be made, and whether any other consents, approvals, permits or authorizations not contemplated by Section 8.2(a) are required to be or should be obtained, from any Governmental Authority under any other applicable Law in connection with the transactions contemplated hereby, and (ii) promptly make any filings, furnish information required in connection therewith and seek to obtain timely any such consents, permits, authorizations, approvals or waivers that the parties determine are required to be or should be made or obtained in connection with the transactions contemplated hereby. (d) Notwithstanding anything to the contrary in this Agreement, in connection with any filing or submission required or action to be taken by either Parent or the Company to consummate the Offer and the Merger, in no event shall Parent or any of its Subsidiaries or Affiliates be obligated to propose or agree to accept any undertaking or condition, to enter into any consent decree, to make any divestiture or accept any operational restriction, or take or commit to take any action (i) the effectiveness or consummation of which is not conditional on the consummation of the Offer and the Merger or (ii) that individually or in the aggregate (x) is or would reasonably be expected to be materially adverse (with materiality, for purposes of this provision, being measured in relation to the size of the Company and its Subsidiaries taken as a whole) to (A) the Company and its Subsidiaries, taken as a whole, or Parent and its Subsidiaries, taken as a whole, either before or after giving effect to the Offer or the Merger, or (B) Parent’s ownership or operation of any material portion of the business or assets of the Company and its Subsidiaries, taken as a whole, or (y) would reasonably be expected to deny Parent the material benefit of the bargains contemplated by the transactions contemplated by this Agreement. The Company shall agree, if requested by Parent in writing, to commit to take any of the forgoing actions with respect to the assets or business of the Company in furtherance of this Section 8.2; provided, however, that any such action may be conditioned upon the consummation of the Merger and other Transactions contemplated by this Agreement.